Olivier Pasquier Joins CYTOO as Chief Commercial Officer
News Mar 18, 2013
Former Senior Marketing Manager Europe at QIAGEN, with more than 10 years experience in biology and biotechnology, he is passionate about biotech breakthroughs. He joins the team to lead the commercial success of CYTOO's 2D+ Cell Culture Platform and develop new markets in cell based assays and screening.
François Chatelain, CEO of CYTOO, says “We're delighted to welcome Olivier at CYTOO: I have no doubt that his insights, energy and business initiatives will be really impactful on CYTOO’s development!"
“It is an honour for me to join the executive team of CYTOO”, says Olivier Pasquier. “This company has a unique talented team, a breakthrough technology, a secured financial background, able to deeply change the game in the cell-based assay science. I want to make sure that every lab using cell culture in the world accesses micropatterns and scientific expertise available at CYTOO.”
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE
New Class of Drugs for the Treatment of Advanced Lung DiseaseNews
Researchers have demonstrated the potential of a new class of drugs for the treatment of refractory chronic obstructive pulmonary disease, i.e. COPD.READ MORE